These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 16640001)

  • 1. Leptin changes in Taiwanese girls with central precocious puberty before and during the GnRH agonist treatment.
    Su PH; Wang SL; Lin CY; Chen JY; Changlai CP; Jian SH; Chen SJ
    Acta Paediatr Taiwan; 2005; 46(5):278-83. PubMed ID: 16640001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum leptin levels in girls with precocious puberty.
    Verrotti A; Basciani F; Trotta D; De Simone M; Morgese G; Chiarelli F
    Diabetes Nutr Metab; 2003 Apr; 16(2):125-9. PubMed ID: 12846452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum leptin levels in patients with progressive central precocious puberty.
    Heger S; Partsch CJ; Peter M; Blum WF; Kiess W; Sippell WG
    Pediatr Res; 1999 Jul; 46(1):71-5. PubMed ID: 10400137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls.
    Houk CP; Kunselman AR; Lee PA
    Pediatrics; 2009 Jun; 123(6):e1059-63. PubMed ID: 19482738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal luteinizing hormone/follicle stimulating hormone ratio in diagnosis of central precocious puberty.
    Supornsilchai V; Hiranrat P; Wacharasindhu S; Srivuthana S; Aroonparkmongkol S
    J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S145-51. PubMed ID: 12929982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin and estradiol as related to change in pubertal status and body weight.
    Larmore KA; O'Connor D; Sherman TI; Funanage VL; Hassink SG; Klein KO
    Med Sci Monit; 2002 Mar; 8(3):CR206-10. PubMed ID: 11889458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?
    Léger J; Reynaud R; Czernichow P
    J Pediatr; 2000 Dec; 137(6):819-25. PubMed ID: 11113839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
    Carel JC; Lahlou N; Jaramillo O; Montauban V; Teinturier C; Colle M; Lucas C; Chaussain JL
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4111-6. PubMed ID: 12213857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of gonadotropin-releasing hormone analogs treatment on final height in girls with central precocious puberty].
    Chen SK; Fan X; Tang Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 May; 11(5):374-6. PubMed ID: 19470261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial growth deceleration during GnRH analogue therapy for precocious puberty.
    Mouat F; Hofman PL; Jefferies C; Gunn AJ; Cutfield WS
    Clin Endocrinol (Oxf); 2009 May; 70(5):751-6. PubMed ID: 19178517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on cases of precocious puberty].
    Nanbu A; Kumamoto Y; Takagi Y; Maruta H
    Hinyokika Kiyo; 1989 Oct; 35(10):1715-20. PubMed ID: 2532862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central precocious puberty: clinical and laboratory features.
    Chemaitilly W; Trivin C; Adan L; Gall V; Sainte-Rose C; Brauner R
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):289-94. PubMed ID: 11298079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment.
    Nam HK; Kim HR; Rhie YJ; Lee KH
    J Korean Med Sci; 2017 Mar; 32(3):475-479. PubMed ID: 28145651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog.
    Verrotti A; Chiarelli F; Montanaro AF; Morgese G
    Gynecol Endocrinol; 1995 Dec; 9(4):277-81. PubMed ID: 8629454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.